These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27434591)

  • 1. Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins.
    Marshall DJ; Harried SS; Murphy JL; Hall CA; Shekhani MS; Pain C; Lyons CA; Chillemi A; Malavasi F; Pearce HL; Thorson JS; Prudent JR
    Mol Ther; 2016 Oct; 24(10):1760-1770. PubMed ID: 27434591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
    Altmann KH
    Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
    [No Abstract]   [Full Text] [Related]  

  • 3. Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.
    Garcia DG; de Castro-Faria-Neto HC; da Silva CI; de Souza e Souza KF; Gonçalves-de-Albuquerque CF; Silva AR; de Amorim LM; Freire AS; Santelli RE; Diniz LP; Gomes FC; Faria MV; Burth P
    Mol Cancer; 2015 May; 14():105. PubMed ID: 25976744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plumbagin-induced oxidative stress leads to inhibition of Na
    Alharbi Y; Kapur A; Felder M; Barroilhet L; Stein T; Pattnaik BR; Patankar MS
    Sci Rep; 2019 Aug; 9(1):11471. PubMed ID: 31391478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
    Feng Y; Wang Y; Zhu Z; Li W; Sussman RT; Randall M; Bosse KR; Maris JM; Dimitrov DS
    MAbs; 2016; 8(4):799-810. PubMed ID: 26910291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Chen Q; Millar HJ; McCabe FL; Manning CD; Steeves R; Lai K; Kellogg B; Lutz RJ; Trikha M; Nakada MT; Anderson GM
    Clin Cancer Res; 2007 Jun; 13(12):3689-95. PubMed ID: 17575234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small targeted cytotoxics from DNA-encoded chemical libraries.
    Samain F; Casi G
    Curr Opin Chem Biol; 2015 Jun; 26():72-9. PubMed ID: 25726911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Na/K-ATPase: Their role in cell adhesion and migration in cancer.
    Silva CID; Gonçalves-de-Albuquerque CF; Moraes BPT; Garcia DG; Burth P
    Biochimie; 2021 Jun; 185():1-8. PubMed ID: 33713729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
    Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
    Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
    Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
    Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Na+/K+-ATPase and cancer.
    Mijatovic T; Dufrasne F; Kiss R
    Pharm Pat Anal; 2012 Mar; 1(1):91-106. PubMed ID: 24236716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates.
    Kulkarni AA; Gukasyan HJ
    Pharm Res; 2015 Nov; 32(11):3451-2. PubMed ID: 26275530
    [No Abstract]   [Full Text] [Related]  

  • 14. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay.
    Wilson R
    Bioanalysis; 2013 May; 5(9):1083-97. PubMed ID: 23641698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
    Jackson D; Stover D
    Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
    Staudacher AH; Brown MP
    Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.